Chiasma, Inc. (CHMA) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up more than 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Chiasma Reports First Quarter 2016 Results
May 11, 2016 4:01 PM EDTWALTHAM, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a biopharmaceutical company developing an investigational new drug, Mycapssa (octreotide) capsules, for the potential maintenance therapy of adult patients with the orphan disease acromegaly, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.
Based on the interest we have seen for an oral somatostatin analog and our clinical data to date, we continue to believe that Mycapssa has the potential to help many patients living with acromegaly, said Mark Leuchtenberger, president and chief executive officer of Chiasma. ... More
